Tenaya Therapeutics heads into today's earnings print with one of the most elevated short scores in the biotech universe — yet the stock has been climbing.
The short side is deeply embedded here. Short interest runs at 16.1% of the free float, and while it has eased about 7% over the past week, it still sits roughly 24% above where it was a month ago. The ORTEX short score of 74.7 places the stock in the bottom 7th percentile of the universe for short positioning — meaning shorts are far more crowded here than in nearly 93% of comparable names. Borrow costs remain modest at 1.3% annualised, up 17% on the week, and availability has loosened from the 52-week tightest levels seen at end of April, suggesting some short covering rather than a new squeeze forming. Days to cover run at 9.1 — it would take shorts over nine trading sessions to exit at current volumes.
Options positioning has swung sharply toward calls ahead of the print. The put/call ratio jumped to 0.033 on Wednesday — nearly four standard deviations above its 20-day average of 0.024. In absolute terms, the ratio is extremely low, meaning call activity dominates overwhelmingly. That aligns with the stock's recent momentum: TNYA has gained nearly 20% over the past week and 14% over the past month, closing at $0.79. Most correlated peers posted more modest moves — gained 6.3% on the week and around 7.7%, making TNYA's rally stand out as stock-specific rather than sector-driven.
The bull case rests on pipeline progress in gene therapy for heart disease, a partnership with Alnylam Pharmaceuticals, and the resolution of a prior FDA clinical hold. Covering analysts — all maintaining Buy ratings — have nonetheless trimmed targets materially over recent months, with HC Wainwright cutting to $3 and Canaccord to $5 in December. The most recent note, from Chardan in March, holds at an $8 target. Against a current price of $0.79, these targets imply massive upside on paper, but the gap is wide enough to reflect deep uncertainty about the timeline to commercialisation rather than a straightforward valuation call. The bear case centres on binary clinical risk, AAV manufacturing complexity, and the absence of clear product differentiation versus peers.
Institutional ownership adds a notable wrinkle. The Column Group holds a 22.7% stake — and sold roughly $2.6 million worth of shares across several tranches in late February, the only material insider activity in the trailing 90 days. That net selling of around $5.9 million in value over 90 days stands as a cautionary footnote against an otherwise call-heavy options setup.
Past earnings reactions at TNYA have been consistently negative over five days regardless of the initial day-one move — the stock fell between 8% and 12% in the five sessions following each of the last three confirmed events. Today's print will test whether the recent rally and aggressive call positioning reflect genuine clinical conviction, or simply short-term momentum running ahead of the data.
See the live data behind this article on ORTEX.
Open TNYA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
